Skip to main content
NCBI home page
Biochemical Journal logoLink to Biochemical Journal
. 1996 Dec 15;320(Pt 3):897–903. doi: 10.1042/bj3200897

Lactoferrin regulates the activity of heparin proteoglycan-bound mast cell chymase: characterization of the binding of heparin to lactoferrin.

G Pejler 1
PMCID: PMC1218013  PMID: 9003378

Abstract

Rat mast cell protease 1 (RMCP-1) is a secretory granule serine protease (chymase) that is recovered in vivo in a macromolecular complex with heparin proteoglycan (PG). We have previously shown that heparin activates RMCP-1 and that RMCP-1, when bound to heparin PG, is largely resistant to inhibition by a variety of macromolecular protease inhibitors. In the search for alternative mechanisms in the regulation of RMCP-1 activity, we hypothesized that heparin antagonists, by interfering with the RMCP-1/heparin PG interaction, might influence the activity of heparin-bound mast cell chymase. In the present study, lactoferrin (LF), a heparin-binding protein, was assessed for RMCP-1 inhibiting activity. LF proved to decrease the activity of heparin PG-associated RMCP-1, although a portion of the enzyme activity was resistant to regulation. The mechanism of regulation was shown to involve the displacement of RMCP-1 from heparin PG, and LF caused an approx. 6-fold increase in the apparent Km of the RMCP-1-heparin PG complex for the chromogenic substrate S-2586. The interaction of LF with heparin was characterized. Pig mucosal heparin and endogenous heparin PG were equally effective in binding LF, whereas heparan sulphate bound with lower affinity. None of dermatan sulphate, chondroitin sulphate or hyaluronan were effective in binding LF. Further, the 6-O-, 2-O- and N-sulphate groups in heparin were of approximately equal importance for binding. Octasaccharides were the smallest heparin oligosaccharides showing significant binding to LF.

Full Text

The Full Text of this article is available as a PDF (431.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashikari S., Habuchi H., Kimata K. Characterization of heparan sulfate oligosaccharides that bind to hepatocyte growth factor. J Biol Chem. 1995 Dec 8;270(49):29586–29593. doi: 10.1074/jbc.270.49.29586. [DOI] [PubMed] [Google Scholar]
  2. BITTER T., MUIR H. M. A modified uronic acid carbazole reaction. Anal Biochem. 1962 Oct;4:330–334. doi: 10.1016/0003-2697(62)90095-7. [DOI] [PubMed] [Google Scholar]
  3. Bellamy W., Takase M., Wakabayashi H., Kawase K., Tomita M. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J Appl Bacteriol. 1992 Dec;73(6):472–479. doi: 10.1111/j.1365-2672.1992.tb05007.x. [DOI] [PubMed] [Google Scholar]
  4. Bourdon M. A., Shiga M., Ruoslahti E. Identification from cDNA of the precursor form of a chondroitin sulfate proteoglycan core protein. J Biol Chem. 1986 Sep 25;261(27):12534–12537. [PubMed] [Google Scholar]
  5. Bromley M., Fisher W. D., Woolley D. E. Mast cells at sites of cartilage erosion in the rheumatoid joint. Ann Rheum Dis. 1984 Feb;43(1):76–79. doi: 10.1136/ard.43.1.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Galli S. J. New concepts about the mast cell. N Engl J Med. 1993 Jan 28;328(4):257–265. doi: 10.1056/NEJM199301283280408. [DOI] [PubMed] [Google Scholar]
  7. Gervasoni J. E., Jr, Conrad D. H., Hugli T. E., Schwartz L. B., Ruddy S. Degradation of human anaphylatoxin C3a by rat peritoneal mast cells: a role for the secretory granule enzyme chymase and heparin proteoglycan. J Immunol. 1986 Jan;136(1):285–292. [PubMed] [Google Scholar]
  8. Gordon J. R., Burd P. R., Galli S. J. Mast cells as a source of multifunctional cytokines. Immunol Today. 1990 Dec;11(12):458–464. doi: 10.1016/0167-5699(90)90176-a. [DOI] [PubMed] [Google Scholar]
  9. Harmsen M. C., Swart P. J., de Béthune M. P., Pauwels R., De Clercq E., The T. H., Meijer D. K. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis. 1995 Aug;172(2):380–388. doi: 10.1093/infdis/172.2.380. [DOI] [PubMed] [Google Scholar]
  10. Hawkins R. A., Claman H. N., Clark R. A., Steigerwald J. C. Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis? Ann Intern Med. 1985 Feb;102(2):182–186. doi: 10.7326/0003-4819-102-2-182. [DOI] [PubMed] [Google Scholar]
  11. Huang R. Y., Blom T., Hellman L. Cloning and structural analysis of MMCP-1, MMCP-4 and MMCP-5, three mouse mast cell-specific serine proteases. Eur J Immunol. 1991 Jul;21(7):1611–1621. doi: 10.1002/eji.1830210706. [DOI] [PubMed] [Google Scholar]
  12. Kjellén L., Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem. 1991;60:443–475. doi: 10.1146/annurev.bi.60.070191.002303. [DOI] [PubMed] [Google Scholar]
  13. Le Trong H., Parmelee D. C., Walsh K. A., Neurath H., Woodbury R. G. Amino acid sequence of rat mast cell protease I (chymase). Biochemistry. 1987 Nov 3;26(22):6988–6994. doi: 10.1021/bi00396a020. [DOI] [PubMed] [Google Scholar]
  14. Levay P. F., Viljoen M. Lactoferrin: a general review. Haematologica. 1995 May-Jun;80(3):252–267. [PubMed] [Google Scholar]
  15. Maccarana M., Casu B., Lindahl U. Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J Biol Chem. 1993 Nov 15;268(32):23898–23905. [PubMed] [Google Scholar]
  16. Maccarana M., Lindahl U. Mode of interaction between platelet factor 4 and heparin. Glycobiology. 1993 Jun;3(3):271–277. doi: 10.1093/glycob/3.3.271. [DOI] [PubMed] [Google Scholar]
  17. Mann D. M., Romm E., Migliorini M. Delineation of the glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin. J Biol Chem. 1994 Sep 23;269(38):23661–23667. [PubMed] [Google Scholar]
  18. Miller J. S., Westin E. H., Schwartz L. B. Cloning and characterization of complementary DNA for human tryptase. J Clin Invest. 1989 Oct;84(4):1188–1195. doi: 10.1172/JCI114284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ogamo A., Nagai A., Nagasawa K. Binding of heparin fractions and other polysulfated polysaccharides to plasma fibronectin: effects of molecular size and degree of sulfation of polysaccharides. Biochim Biophys Acta. 1985 Jul 26;841(1):30–41. [PubMed] [Google Scholar]
  20. Pejler G., Berg L. Regulation of rat mast cell protease 1 activity. Protease inhibition is prevented by heparin proteoglycan. Eur J Biochem. 1995 Oct 1;233(1):192–199. doi: 10.1111/j.1432-1033.1995.192_1.x. [DOI] [PubMed] [Google Scholar]
  21. Pejler G., Karlström A. R., Berg L. Identification of the proteolytic thrombin fragments formed after cleavage with rat mast cell protease 1. Eur J Biochem. 1995 Jan 15;227(1-2):102–107. doi: 10.1111/j.1432-1033.1995.tb20364.x. [DOI] [PubMed] [Google Scholar]
  22. Pejler G., Karlström A. Thrombin is inactivated by mast cell secretory granule chymase. J Biol Chem. 1993 Jun 5;268(16):11817–11822. [PubMed] [Google Scholar]
  23. Pejler G., Lindahl U., Larm O., Scholander E., Sandgren E., Lundblad A. Monoclonal antibodies specific for oligosaccharides prepared by partial nitrous acid deamination of heparin. J Biol Chem. 1988 Apr 15;263(11):5197–5201. [PubMed] [Google Scholar]
  24. Pejler G., Maccarana M. Interaction of heparin with rat mast cell protease 1. J Biol Chem. 1994 May 20;269(20):14451–14456. [PubMed] [Google Scholar]
  25. Pejler G., Söderström K., Karlström A. Inactivation of thrombin by a complex between rat mast-cell protease 1 and heparin proteoglycan. Biochem J. 1994 Apr 15;299(Pt 2):507–513. doi: 10.1042/bj2990507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Qureshi R., Jakschik B. A. The role of mast cells in thioglycollate-induced inflammation. J Immunol. 1988 Sep 15;141(6):2090–2096. [PubMed] [Google Scholar]
  27. Reynolds D. S., Stevens R. L., Lane W. S., Carr M. H., Austen K. F., Serafin W. E. Different mouse mast cell populations express various combinations of at least six distinct mast cell serine proteases. Proc Natl Acad Sci U S A. 1990 Apr;87(8):3230–3234. doi: 10.1073/pnas.87.8.3230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Saarinen J., Kalkkinen N., Welgus H. G., Kovanen P. T. Activation of human interstitial procollagenase through direct cleavage of the Leu83-Thr84 bond by mast cell chymase. J Biol Chem. 1994 Jul 8;269(27):18134–18140. [PubMed] [Google Scholar]
  29. Schechter N. M., Choi J. K., Slavin D. A., Deresienski D. T., Sayama S., Dong G., Lavker R. M., Proud D., Lazarus G. S. Identification of a chymotrypsin-like proteinase in human mast cells. J Immunol. 1986 Aug 1;137(3):962–970. [PubMed] [Google Scholar]
  30. Schwartz L. B., Riedel C., Caulfield J. P., Wasserman S. I., Austen K. F. Cell association of complexes of chymase, heparin proteoglycan, and protein after degranulation by rat mast cells. J Immunol. 1981 Jun;126(6):2071–2078. [PubMed] [Google Scholar]
  31. Stevens R. L., Austen K. F. Recent advances in the cellular and molecular biology of mast cells. Immunol Today. 1989 Nov;10(11):381–386. doi: 10.1016/0167-5699(89)90272-7. [DOI] [PubMed] [Google Scholar]
  32. Suzuki S., Pierschbacher M. D., Hayman E. G., Nguyen K., Ohgren Y., Ruoslahti E. Domain structure of vitronectin. Alignment of active sites. J Biol Chem. 1984 Dec 25;259(24):15307–15314. [PubMed] [Google Scholar]
  33. Thunberg L., Bäckström G., Lindahl U. Further characterization of the antithrombin-binding sequence in heparin. Carbohydr Res. 1982 Mar 1;100:393–410. doi: 10.1016/s0008-6215(00)81050-2. [DOI] [PubMed] [Google Scholar]
  34. VIldé J. L., Breton-Gorius J., Hakim J., Buriot D., Griscelli C. Congenital and acquired lactoferrin deficiencies in neutrophils. Adv Exp Med Biol. 1982;141:611–620. doi: 10.1007/978-1-4684-8088-7_60. [DOI] [PubMed] [Google Scholar]
  35. Wang D., Pabst K. M., Aida Y., Pabst M. J. Lipopolysaccharide-inactivating activity of neutrophils is due to lactoferrin. J Leukoc Biol. 1995 Jun;57(6):865–874. doi: 10.1002/jlb.57.6.865. [DOI] [PubMed] [Google Scholar]
  36. Wu H. F., Lundblad R. L., Church F. C. Neutralization of heparin activity by neutrophil lactoferrin. Blood. 1995 Jan 15;85(2):421–428. [PubMed] [Google Scholar]
  37. Wu H. F., Monroe D. M., Church F. C. Characterization of the glycosaminoglycan-binding region of lactoferrin. Arch Biochem Biophys. 1995 Feb 20;317(1):85–92. doi: 10.1006/abbi.1995.1139. [DOI] [PubMed] [Google Scholar]
  38. Yurt R., Austen K. F. Preparative purification of the rat mast cell chymase: characterization and interaction with granule components. J Exp Med. 1977 Nov 1;146(5):1405–1419. doi: 10.1084/jem.146.5.1405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Zou S., Magura C. E., Hurley W. L. Heparin-binding properties of lactoferrin and lysozyme. Comp Biochem Physiol B. 1992 Dec;103(4):889–895. doi: 10.1016/0305-0491(92)90210-i. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES